Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vittorio Bertele'

Showing results (1-10 of 68) with videos related to

Pageof 7
Sort By:
BMJ (Clinical Research Ed.)|August 3, 2002
Efficacy, safety, and cost of new anticancer drugsSilvio Garattini, Vittorio Bertele
BMJ (Clinical Research Ed.)|October 8, 2010
Rosiglitazone and the need for a new drug safety agencySilvio Garattini, Vittorio Bertele'
European Journal of Internal Medicine|May 25, 2010
Alternative medical practices: flashbacks from the Dark AgesSilvio Garattini, Vittorio Bertele'
Recenti Progressi in Medicina|January 27, 2007
[False innovations in clinical research]Silvio Garattini, Vittorio Bertele'
Lancet (London, England)|October 26, 2007
Non-inferiority trials are unethical because they disregard patients' interestsSilvio Garattini, Vittorio Bertele'
Nature|July 17, 2015
Health care: Make pharma justify the price of drugsVittorio Bertele', Silvio Garattini
The New England Journal of Medicine|January 19, 2018
Noninferiority TrialsSilvio Garattini, Vittorio Bertele’
Journal of Hepatology|August 12, 2009
Ethics in clinical researchSilvio Garattini, Vittorio Bertele'
BMJ (Clinical Research Ed.)|April 1, 2010
Europe's opportunity to open up drug regulationSilvio Garattini, Vittorio Bertele'
Expert Review of Pharmacoeconomics & Outcomes Research|October 8, 2009
Toward new legislation on drugs in EuropeSilvio Garattini, Vittorio Bertele'
Pageof 7

Showing results (1-10 of 68) with videos related to

Sort By:
Pageof 7
BMJ (Clinical Research Ed.)|August 3, 2002
Efficacy, safety, and cost of new anticancer drugsSilvio Garattini, Vittorio Bertele
BMJ (Clinical Research Ed.)|October 8, 2010
Rosiglitazone and the need for a new drug safety agencySilvio Garattini, Vittorio Bertele'
European Journal of Internal Medicine|May 25, 2010
Alternative medical practices: flashbacks from the Dark AgesSilvio Garattini, Vittorio Bertele'
Recenti Progressi in Medicina|January 27, 2007
[False innovations in clinical research]Silvio Garattini, Vittorio Bertele'
Lancet (London, England)|October 26, 2007
Non-inferiority trials are unethical because they disregard patients' interestsSilvio Garattini, Vittorio Bertele'
Nature|July 17, 2015
Health care: Make pharma justify the price of drugsVittorio Bertele', Silvio Garattini
The New England Journal of Medicine|January 19, 2018
Noninferiority TrialsSilvio Garattini, Vittorio Bertele’
Journal of Hepatology|August 12, 2009
Ethics in clinical researchSilvio Garattini, Vittorio Bertele'
BMJ (Clinical Research Ed.)|April 1, 2010
Europe's opportunity to open up drug regulationSilvio Garattini, Vittorio Bertele'
Expert Review of Pharmacoeconomics & Outcomes Research|October 8, 2009
Toward new legislation on drugs in EuropeSilvio Garattini, Vittorio Bertele'
Pageof 7